Cathay HAITONG: Leading the technological iteration into the autoimmune 3.0 era, with密集catalysts anticipated in 2026 to drive industrial transformation.

The autoimmune drug sector is currently on the verge of a boom in the 3.0 era, as data from the next generation of autoimmune drugs, both domestically and internationally, are gradually being released. The path and trends of drug iteration will become increasingly clear.

Zhitong FinanceMay 7 10:51

As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

Keymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate

TipRanksApr 29 17:22

KEYMED BIO-B: 2025 ANNUAL REPORT

HKEXApr 29 16:44 · Announcements

Cathay Pacific Haitong: The billion-dollar autoimmune sector is undergoing a generational shift as multinational corporations (MNCs) accelerate their efforts to secure the next-generation pipeline.

Self-administered major drugs are an important cornerstone of MNC's existing business; as patents approach expiration, MNCs are accelerating the development of the next generation of self-administered pipelines.

Zhitong FinanceApr 17 16:37

Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal

TipRanksApr 15 22:13